Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Max S Mano

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
Breast Cancer Research and Treatment|July 31, 2020
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)Daniela Dornelles Rosa, José Bines, Gustavo Werutsky, et al.
The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Clinical Breast Cancer|June 8, 2026
Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment ResponseJúlio Cesar Prestes, Andre Guimares Gouveia, Maurício Fraga da Silva, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
The New England Journal of Medicine|December 6, 2018
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast CancerGunter von Minckwitz, Chiun-Sheng Huang, Max S Mano, et al.
Breast Cancer Research and Treatment|July 31, 2020
The impact of sociodemographic factors and health insurance coverage in the diagnosis and clinicopathological characteristics of breast cancer in Brazil: AMAZONA III study (GBECAM 0115)Daniela Dornelles Rosa, José Bines, Gustavo Werutsky, et al.
The New England Journal of Medicine|January 15, 2025
Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast CancerCharles E Geyer, Michael Untch, Chiun-Sheng Huang, et al.
Clinical Breast Cancer|June 8, 2026
Survival After Multimodal Treatment for Breast Cancer in Brazil: The Predominant Role of Clinical Stage and Treatment ResponseJúlio Cesar Prestes, Andre Guimares Gouveia, Maurício Fraga da Silva, et al.
Pageof 5